Intercontinental Information Sciences, Eli Lilly Australia Pty Ltd, Macquarie Park, NSW, Australia.
Int J Clin Pract. 2011 Sep;65(9):945-53. doi: 10.1111/j.1742-1241.2011.02743.x.
This study compared all-cause medication discontinuation (any switch, augmentation or medication discontinuation) in matched cohorts of patients with schizophrenia who were initiated on depot or oral antipsychotics. Other objectives included between-group comparisons of resource use, and clinical and functional outcomes.
This post hoc analysis of a one-year, multicentre, prospective, observational study included outpatients with schizophrenia who required a change in their antipsychotic medication because of a physician-perceived risk of medication non-adherence. Patients were matched 1 : 1 using an optimal algorithm with rank-based Mahalanobis distances. All-cause medication discontinuation was compared using the Klein and Moeschberger test for survival and hazard ratios (HR) with 95% confidence intervals (CI) were calculated using a Cox proportional hazards model, stratifying on matched pairs.
Forty patients who initiated a depot antipsychotic could be matched to patients who initiated an oral antipsychotic. Fewer depot-treated patients discontinued their antipsychotic medication at least once compared with oral-treated patients [20% (8/40) vs. 40% (16/40)]. Depot-treated patients discontinued their medication later (Klein and Moeschberger test p = 0.025) and were less likely to discontinue their initial antipsychotic medication [HR = 0.33 (95% CI, 0.12-0.92), p = 0.033] than oral-treated patients. There were few differences in resource use and no differences in clinical and functional outcomes between cohorts.
In this matched-cohort analysis, patients with schizophrenia who were considered to be non-adherent with their prior oral antipsychotics were less likely to discontinue their medication for any cause if they were initiated on depot compared with oral antipsychotics.
本研究比较了因医生认为药物依从性风险而需要更换抗精神病药物的精神分裂症患者,接受长效和口服抗精神病药物治疗的全因药物停药(任何换药、加药或停药)情况。其他目标包括组间资源利用、临床和功能结局比较。
这是一项为期 1 年、多中心、前瞻性、观察性研究的事后分析,纳入了因医生认为药物依从性风险而需要更换抗精神病药物的精神分裂症门诊患者。根据最优算法和基于等级的马哈拉诺比斯距离对患者进行 1:1 匹配。使用生存 Klein 和 Moeschberger 检验和 Cox 比例风险模型比较全因药物停药,该模型对匹配对进行分层,并计算危险比(HR)及其 95%置信区间(CI)。
40 例起始长效抗精神病药物的患者可以与起始口服抗精神病药物的患者匹配。与口服治疗组相比,长效治疗组至少停药一次的患者更少[20%(8/40)比 40%(16/40)]。长效治疗组停药时间较晚(Klein 和 Moeschberger 检验,p = 0.025),初始抗精神病药物停药的可能性较小[HR = 0.33(95% CI,0.12-0.92),p = 0.033]。两组资源利用差异较小,临床和功能结局无差异。
在这项匹配队列分析中,与起始口服抗精神病药物相比,被认为对先前口服抗精神病药物依从性差的精神分裂症患者,如果起始长效抗精神病药物治疗,因任何原因停药的可能性更小。